Table 3.
Survival Results by FLT3 Status
| (a). Patients with CBF-AML | |||
|---|---|---|---|
| Parameter (95% CI) | FLT3-Mutated (N =13) | wt-FLT3 (N = 52) | p |
| DFS, 2 years | 50% (14–95%) | 64% (47–83%) | 0.66 |
| Median, weeks | NR (82-NR) | NR (84-NR) | |
| EFS, 2 years | 50% (12–88%) | 58% (41–75%) | 0.84 |
| Median, weeks | 100 (86-NR) | NR (73-NR) | |
| OS, 2 years | 92% (76–100%) | 74% (59–88%) | 0.57 |
| Median, weeks | NR (112-NR) | NR (112-NR) | |
| (b). Patients with NK-AML | |||||
|---|---|---|---|---|---|
| Parameter (95% CI) | FLT3-ITD (N = 69)1 | FLT3-TKD (N = 18) | wt-FLT3 (N = 185) | p (ITD vs WT) | P (TKD vs WT) |
| DFS, 2 years | 10% (0–21%) | 49% (14–84%) | 40% (30–50%) | 0.001 | 0.15 |
| Median, weeks | 28 (21–35) | 102 (45-NR) | 63 (41–85) | ||
| EFS, 2 years | 6% (0–11%) | 48% (23–74%) | 26% (19–34%) | < 0.00001 | 0.15 |
| Median, weeks | 20 (12–24) | 61 (0–132) | 41 (29–52) | ||
| OS, 2 years | 13% (2.5–23%) | 43% (13–73%) | 47% (39–56%) | < 0.00001 | 0.85 |
| Median, weeks | 33 (29–37) | 84 (58–110) | 90 (53–126) | ||
| (c). Patients with Poor Risk-AML | |||
|---|---|---|---|
| Parameter (95% CI) | FLT3-Mutated (N =11) | wt-FLT3 (N = 133) | p |
| EFS, 2 years | 0% (0%) | 6% (1–10%) | 0.37 |
| Median, weeks | 8 (5–11) | 11 (7–15) | |
| OS, 2 years | 0% (0%) | 11% (5–17%) | 0.44 |
| Median, weeks | 55 (35–74) | 24 (18–30) | |
Abbreviations: CR, complete remission; DFS, disease-free survival; EFS, event-free survival; OS, overall survival; NR, not reached.
Abbreviations: CR, complete remission; DFS, disease-free survival; EFS, event-free survival; OS, overall survival; NR, not reached.
1
Includes 10 patients with double mutations
Abbreviations: CR, complete remission; DFS, disease-free survival; EFS, event-free survival; OS, overall survival; NR, not reached.